Injective (INJ) is building renewed bullish momentum following a significant breakout from its prior accumulation phase. A fresh MACD crossover lends additional technical strength, while recent developments in real-world asset (RWA) tokenization and artificial intelligence integration are reinforcing Injective’s role in the evolving digital financial sector.
Technical momentum and resistance levels
INJ has recently exited a prolonged consolidation zone after moving between approximately $3.80 and $5.00, with price advancing to a peak near $8.25 before consolidating around $7.79. The token consistently trades above its main exponential moving averages, and the 20-day EMA located at $6.06 is emerging as a crucial support area in the event of short-term declines.
Momentum indicators remain robust. The Relative Strength Index is currently measured at 70.80, above its moving average of 62.57, underscoring persistent buyer interest. However, this high RSI reading also brings INJ close to overbought territory, raising the possibility of near-term consolidation before any further sustained rally.
Crypto analyst JAVON MARKS highlighted that INJ gained about 53% since a previous bullish MACD crossover. He identified a new crossover forming, pointing to further upside toward a $60 target. MARKS noted that a historical crossover preceded a rally of over 3,300%, although he advised that such past performance does not guarantee a repetition.
MARKS suggested, “A fresh MACD crossover could open the path toward the $60 objective if bullish momentum holds and critical support levels are preserved.”
Support at $7.40 remains essential for bulls aiming to maintain the breakout. A potential breach could push INJ down to the 50-day EMA near $5.51, with traders monitoring these areas for confirmation that the broader structure remains intact.
| Level | Approximate Value | Significance |
|---|---|---|
| Short-term support (20-day EMA) | $6.06 | Dynamic support; near-term pullback zone |
| Critical support zone | $7.40 | Holds bullish momentum above breakout |
| Major support (50-day EMA) | $5.51 | Potential downside target if $7.40 fails |
| Upside target | $60.00 | Longer-term technical objective |
AI initiatives and RWA tokenization pilot
Beyond technical trends, Injective is advancing its position in the sector through RWA infrastructure development, institutional-grade adoption, and AI-driven financial applications. The network is building a platform that combines asset issuance, trading, settlement, compliance, recordkeeping, and AI-based operations into an on-chain ecosystem.
Recently, Injective launched a pilot related to trade finance, in collaboration with POSCO International and LG CNS. This initiative involved automating on-chain transactions using trade receivables derived from actual business operations. Artificial intelligence agents checked letters of credit and trade documents, while the receivables themselves were issued as permissioned tokens.
Mini dictionary: POSCO International and LG CNS are major South Korean companies. POSCO International operates in steel trading and resources, while LG CNS is an IT services and solutions provider. Their collaboration with Injective highlights cross-industry applications for blockchain finance and AI.
Institutional adoption and global expansion
Injective recently obtained registration as a transfer agent with the US Securities and Exchange Commission (SEC), allowing it to offer regulated recordkeeping services on its blockchain. The platform has processed more than $1 billion in real estate mortgages, alongside institutional capital, public equities, trade finance, and pre-IPO investment access in firms like SpaceX and OpenAI.
Injective is also scheduled to co-host an event with Microsoft at Token2049 Singapore on October 6, focusing on “on-chain agentic commerce.” The event will bring together developers, investors, and AI specialists, marking a milestone in Injective’s expansion into AI-powered and blockchain-based financial services.
Analysts observe that a convergence of strong technical signals and Injective’s ongoing institutional partnerships are positioning the project favorably for continued momentum.
Going forward, the $7.40 support zone, along with dynamic EMA levels, will be important reference points for investors tracking the strength of INJ’s uptrend. Any clear breakout above recent highs may accelerate further upside, while rejection at current levels could lead to more consolidation in the short term.
